Clinical Trial

A PhaseⅠ/Ⅱ Study of Simmitinib or Irinotecan Liposomes Combined With DP303c in Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma

Not Yet Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This study is divided into two parts: Cohort 1 and Cohort 2. Cohort 1 includes the dose escalation phase of DP303c combined with simmitinib, as well as the randomized controlled trial (RCT) phase of DP303c combined with simmitinib; Cohort 2 includes dose escalation/dose extension of DP303c combined with irinotecan liposomes, as well as RCT stage of DP303c combined with irinotecan liposomes.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-08-27.
Trial Details
NCT Number NCT06577376
Lead Sponsor Shanghai Runshi Pharmaceutical Technology Co., Ltd
Conditions Localized Advanced or Metastatic Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma, Expressing Human Epidermal Growth Factor Receptor-2 (HER-2), Disease Progression After Receiving at Least One and at Most Two Lines of Systemic Treatment in the Past
Enrollment 252 participants
Start Date 2024-08-26
Primary Completion 2026-08-26 (estimated)
Study Completion 2027-08-26 (estimated)
Updated on ClinicalTrials.gov 2024-09-05